ENSC — Ensysce Biosciences Cashflow Statement
0.000.00%
- $3.30m
- -$0.19m
- $2.23m
- 39
- 44
- 24
- 28
Annual cashflow statement for Ensysce Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 0.366 | 4.31 | -29.1 | -24.2 | -10.6 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | -4.25 | -5.92 | 21.9 | 0.778 | 0.775 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 2.46 | 0.749 | -0.954 | 5.54 | -0.928 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Cash from Operating Activities | -1.42 | -0.864 | -8.24 | -17.9 | -10.8 |
Other Investing Cash Flow Items | 11.9 | 183 | — | 0.004 | 0 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Cash from Investing Activities | 11.9 | 183 | — | 0.004 | 0 |
Financing Cash Flow Items | -0.009 | — | -0.489 | -1.14 | -0.9 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -11 | -184 | 20.3 | 8.77 | 8.76 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.597 | -1.01 | 12.1 | -9.12 | -2.02 |